Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
This observational study follows patients with relapsing multiple sclerosis RMS who are being treated with approved injectable or selected oral disease-modifying therapies DMTs in Germany. The study is non-interventional and open-label, designed to collect real-world data on treatment and disease progression over several years. It aims to understand how patients continue their baseline treatments and how these treatments impact various health and quality of life measures. Participants receive routine medical care with approved injectable or oral DMTs such as ofatumumab, interferon b21, glatiramer acetate, teriflunomide, dimethyl fumarate, or diroximel fumarate. The study includes two cohorts with up to approximately two years of prospective observation each, with an optional extension allowing up to four years total. Treatment decisions and monitoring follow the patients usual care and physicians discretion, including routine visits and telemedicine options. During the study, participants provide medical history, complete questionnaires, and have data collected on disability status, MRI findings, relapses, and laboratory tests. Researchers assess treatment continuation rates, fatigue, anxiety, depression, quality of life, lesion counts, and relapse rates at multiple time points. Safety and treatment interruptions are also documented. Follow-up is flexible and based on standard care procedures, with data collection occurring throughout the observational periods.
Actively Recruiting
Researchers are evaluating the safety and performance of the Oncomagnetic Device, a portable wearable noninvasive magnetic device, in patients newly diagnosed with Glioblastoma Multiforme GBM. This non-randomized, multicenter, open-label clinical investigation uses an exposure-time escalation approach to understand how the device works over increasing durations of daily use. The study aims to provide important information on the devices clinical safety and effectiveness in this patient population. Participants will start using the Oncomagnetic Device for 4 hours per day. If no issues arise after 2 weeks, the daily use will increase to 6 hours, then to 8 hours after another 2 weeks without problems. If any device-related issues occur, the usage time may be reduced by 4 hours per day, with a minimum use of 2 hours daily, adjusted as needed. This personalized escalation continues throughout the study. During the study, participants will be monitored for safety and device performance for at least 6 months, with some evaluations extending up to 3 years. Assessments include clinical reviews and MRI scans to track disease status and any side effects. The main outcome is to assess safety within 6 months, while secondary outcomes focus on device performance over 6 months and up to 3 years. Participants must comply with all procedures and be available for the duration of the investigation.
Actively Recruiting
Researchers are investigating the real-world use and effects of ovarian function suppression OFS combined with endocrine therapy in pre- and perimenopausal women with breast cancer who have low genomic risk according to MammaPrint testing. The study aims to understand differences in treatment outcomes based on menopausal status, chemotherapy use, and endocrine therapies, with a focus on adherence and quality of life over time. This observational registry will collect data to provide insights into treatment paths, outcomes, and factors influencing prognosis in these patients. Participants receive standard-of-care endocrine therapy with or without ovarian suppression and may have received chemotherapy based on clinical decisions and genomic risk assessments. The registry observes various treatment approaches in a real-world setting, including management of ovarian function, and follows patients for up to 10 years. Quality of life assessments occur regularly during the first five years, and treatment adherence is monitored throughout the study period. During the study, participants medical data including baseline characteristics, treatment details, relapse information, and quality of life questionnaires will be collected at multiple time points. Researchers will evaluate outcomes such as distant recurrence-free interval, disease-free survival, overall survival, and endocrine response over 5 to 10 years. The long-term follow-up allows for detailed monitoring of treatment adherence and correlation of genomic and clinicopathological markers with patient outcomes.
Actively Recruiting
Researchers are evaluating the safety and performance of the BeGraft Aortic balloon expandable covered Stent Graft System and the BeGraft Peripheral balloon expandable covered Stent Graft System in treating extensive aorto-iliac occlusive disease. This prospective, multi-center study focuses on using these devices in Covered Endovascular Reconstruction of Aortic Bifurcation CERAB procedures to treat this condition. The study aims to assess how well these stent graft systems work and their safety when implanted as covered stents in the affected arteries. The study involves using the BeGraft Aortic and BeGraft Peripheral covered stent graft systems during CERAB, a minimally invasive technique that rebuilds diseased aortic bifurcation and iliac arteries. These stents are introduced through arteries in the groin or arm to restore blood flow. The procedure uses up to three peripheral stents per limb and targets lesions with significant narrowing or blockage. The devices are evaluated without the need for chimney techniques, and specific sizing and placement criteria apply. Participants will undergo follow-up visits to assess outcomes such as freedom from needing additional treatment at 12 months and incidence of serious device-related adverse effects. Other evaluations include technical success, vessel patency, need for surgical conversion, patient-reported outcomes, clinical success, hemodynamic improvements, and safety monitored at various intervals up to 24 months. Participants must provide consent and attend scheduled follow-ups to track the stents performance and safety over time.